Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 14;38(3):380-399.e13.
doi: 10.1016/j.ccell.2020.06.002. Epub 2020 Jul 9.

Immunogenomic Landscape of Hematological Malignancies

Olli Dufva  1 , Petri Pölönen  2 , Oscar Brück  1 , Mikko A I Keränen  3 , Jay Klievink  3 , Juha Mehtonen  2 , Jani Huuhtanen  3 , Ashwini Kumar  4 , Disha Malani  4 , Sanna Siitonen  5 , Matti Kankainen  1 , Bishwa Ghimire  4 , Jenni Lahtela  4 , Pirkko Mattila  4 , Markus Vähä-Koskela  4 , Krister Wennerberg  4 , Kirsi Granberg  6 , Suvi-Katri Leivonen  7 , Leo Meriranta  7 , Caroline Heckman  8 , Sirpa Leppä  9 , Matti Nykter  6 , Olli Lohi  10 , Merja Heinäniemi  11 , Satu Mustjoki  12
Affiliations
Free article

Immunogenomic Landscape of Hematological Malignancies

Olli Dufva et al. Cancer Cell. .
Free article

Erratum in

  • Immunogenomic Landscape of Hematological Malignancies.
    Dufva O, Pölönen P, Brück O, Keränen MAI, Klievink J, Mehtonen J, Huuhtanen J, Kumar A, Malani D, Siitonen S, Kankainen M, Ghimire B, Lahtela J, Mattila P, Vähä-Koskela M, Wennerberg K, Granberg K, Leivonen SK, Meriranta L, Heckman C, Leppä S, Nykter M, Lohi O, Heinäniemi M, Mustjoki S. Dufva O, et al. Cancer Cell. 2020 Sep 14;38(3):424-428. doi: 10.1016/j.ccell.2020.08.019. Cancer Cell. 2020. PMID: 32931743 No abstract available.

Abstract

Understanding factors that shape the immune landscape across hematological malignancies is essential for immunotherapy development. We integrated over 8,000 transcriptomes and 2,000 samples with multilevel genomics of hematological cancers to investigate how immunological features are linked to cancer subtypes, genetic and epigenetic alterations, and patient survival, and validated key findings experimentally. Infiltration of cytotoxic lymphocytes was associated with TP53 and myelodysplasia-related changes in acute myeloid leukemia, and activated B cell-like phenotype and interferon-γ response in lymphoma. CIITA methylation regulating antigen presentation, cancer type-specific immune checkpoints, such as VISTA in myeloid malignancies, and variation in cancer antigen expression further contributed to immune heterogeneity and predicted survival. Our study provides a resource linking immunology with cancer subtypes and genomics in hematological malignancies.

Keywords: antigen presentation; cancer; epigenomics; genomics; hematology; immune checkpoint; immunology; immunotherapy; leukemia; lymphoma.

PubMed Disclaimer

Conflict of interest statement

Declaration of Interests S.M. has received honoraria and research funding from Novartis, Pfizer, and Bristol-Myers Squibb, and C.H. received funding from Celgene, Novartis, Oncopeptides, Orion Pharma, and the Innovative Medicines Initiative project HARMONY. The remaining authors declare no competing interests.

Comment in

Publication types

MeSH terms